
CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.
ZNF432 (zinc finger protein 432) encodes a zinc finger protein with damaged DNA-binding and protein-macromolecule adaptor activities. It participates in the cellular DNA damage response and is localized in the nucleoplasm. Through its DNA- and protein-binding properties, ZNF432 may contribute to coordination of molecular responses to damaged DNA, although its specific targets and mechanisms remain incompletely characterized.
AGS is a human gastric adenocarcinoma cell line established from a primary stomach tumor of a 54-year-old female patient who had not received prior anticancer treatment. The cells are derived from gastric adenocarcinoma and are used as a model for studying gastric cancer biology, tumor-related signaling pathways, infection-related mechanisms, and therapeutic responses. AGS cells have been reported to carry persistent parainfluenza virus type 5 (PIV5) infection.
Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 3
Reference Transcript: NM_014650
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?